Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Zimbabwe has been experiencing steady growth in recent years.
Customer preferences: With the increasing incidence of autoimmune diseases and organ transplants in Zimbabwe, there has been a growing demand for immunosuppressants. Patients with autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis require long-term treatment with immunosuppressants to manage their symptoms. Additionally, the number of organ transplants has been increasing in Zimbabwe, and immunosuppressants are a critical component of post-transplant care.
Trends in the market: The Zimbabwean government has been taking steps to improve access to healthcare services, including the provision of essential medicines. This has led to an increase in the availability of immunosuppressants in the country. However, the high cost of these drugs remains a barrier to access for many Zimbabweans. As a result, there has been a growing trend towards the use of generic immunosuppressants, which are more affordable than their branded counterparts.
Local special circumstances: Zimbabwe has a high burden of infectious diseases such as HIV/AIDS and tuberculosis, which can increase the risk of complications in patients taking immunosuppressants. Healthcare providers in Zimbabwe must carefully balance the benefits and risks of immunosuppressive therapy in these patients. Additionally, the country's economic challenges have led to shortages of essential medicines, including immunosuppressants.
Underlying macroeconomic factors: Zimbabwe has been experiencing economic challenges in recent years, including high inflation and a shortage of foreign currency. These challenges have led to a decline in the country's healthcare system, including the availability of essential medicines. Additionally, the COVID-19 pandemic has placed additional strain on the healthcare system, leading to disruptions in the supply chain of medicines. Despite these challenges, the Zimbabwean government has been working to improve access to healthcare services and essential medicines, including immunosuppressants.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
